Genentech is announcing positive results for its multiple sclerosis treatment. The South San Francisco company says its phase two study of fenebrutinib significantly reduced MS disease activity in the brain. The drug is now in phase three trials.
Sonya Blakey is a household name when it comes to radio. Beginning her career in Chicago more than 20 years ago, she currently hosts "Sonya Blakey In...Full Bio